Document is current

Article History

Received: 7 August 2020

Accepted: 15 September 2020

First Online: 28 September 2020

Compliance with ethical standards

:

: Baeck J, Brown K.S, Le L, and Riley G are currently employees of Jounce Therapeutics, Inc. Le L also holds stock in Jounce Therapeutics, Inc. prior to employment. Papadopoulos K received funding to START for conduct of this clinical trial from Jounce Therapeutics, Inc; funding to START for conduct of clinical trials from AbbVie, MedImmune, Daiichi Sankyo, Regeneron, Sanofi, ArQule, other from Amgen, other Calithera Biosciences, Curegenix, Incyte, Merck, Peloton Therapeutics, ADC Therapeutics, 3D Medicines, Formation Biologics, EMD Serono, Syros Pharmaceuticals, Mersana, OncoMed, MabSpace Biosciences and Jounce Therapeutics, Inc.; advisory board fees from Arqule, Basilia and Bayer. Falchook S has received royalties from Wolters Kluwer, travel fees from Bristol-Myers Squibb, EMD Serono, Fujifilm, Millennium, Sarah Cannon Research institute and has provided an advisory role to Fujifilm and EMD Serono; received research funding from 3-V Biosciences, Abbisko, Abbvie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Bioatla, Biothera, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce Therapeutics, Inc., Kolltan, Loxo, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Novartis, OncoMed, Oncothyreon, Precision Oncology, Prelude, Regeneron, Rgenix, Ribon, Strategia, Syndax, Taiho, Takeda, Tarveda, Tesaro, Tocagen, Turning Point Therapeutics, U.T. MD Anderson Cancer Center, Vegenics, Xencor. Lakhani N has received research funding from Alexion, Apexian, Beigene, Cerulean, Constellation, CytomX, Formation Biologics, Forty Seven, Ikena, Incyte, Innovent Biologics (includes personal fees), Livzon, Lozo, Macrogenics, Merck, Northern Biologics, Odonate Therapeutics, Pfizer, Regeneron, Symphogen, TaiRx. Wang J has received research funding from Acerta Pharma/Astra Zeneca, ADC Therapeutics, Agenus, Aileron Therapeutics, Astra Zeneca (including speaker fees), Astra Zeneva/MedImmune, Bicycle Therapeutics, BioNTech AG, Boehringer Ingelheim, Calithera Biosciences, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Curis, Cyteir, Daiichi Sankyo, eFFECTOR Therapeutics, Lilly, EMD Serono, Evelo Therapeutics, Genetech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Pharmaceutical, Hutchinson MediPharma, Ignyta, Incyte, Jacobio, Janssen Research and Development, Jounce Therapeutics, Inc., Klus Pharma Kymab, Loxo, LSK Bipartners, Lycera, Macrogenics, Merck, Millenium Pharmaceuticals, Mirati Therapeutics, Moderna Therapeutics, Pfizer, Phoenix Pharmaceuticals, Placon, Portola Pharmaceuticals, Prelude Therapeutics, QiLu Pharmaceutical, Revolution Medicines, Ribon Therapeutics, Birdie, Syndax, Synthorx, Stemline Therapeutics, Taiho Pharmaceutical, Takeda, Tesaro, TopAlliance Biosciences Inc., Vedanta Biosciences, Verastem, Vigeo, Xencor. Gordon G is a paid consultant to Jounce Therapeutics, Inc. and has also been a paid consultant in the last 12 months to Agios, Ayala Pharmaceuticals, Brickell Biotech, FluGen, Heron Therapeutics, Jounce Therapeutics, Inc., OnKure Therapeutics, Prevacept Infection Control, and Zentalis Pharmaceuticals.

: This study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the ethical principles described in the Declaration of Helsinki. Written informed consent was obtained from patients using a form that was approved by the sponsor and the Institutional Review Board/Ethics committee and was in accordance with Good Clinical Practice.

: All authors provided consent for publication of this manuscript.